CIC
ANIP icon

Carnegie Investment Counsel’s ANI Pharmaceuticals ANIP Stock Holding History

Carnegie Investment Counsel’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Sell
2,600
-200
-7% -$16K ﹤0.01% 530
2026
Q1 		$215K Hold
2,800
– – ﹤0.01% 535
2025
Q4 		$221K Buy
+2,800
New +$242K ﹤0.01% 537

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Carnegie Investment Counsel's ANIP Position: Q2 2026 in Review

Carnegie Investment Counsel reduced its ANI Pharmaceuticals (ANIP) stake by 7.1% in Q2 2026, selling an estimated $16K and leaving 2,600 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #530.

Carnegie Investment Counsel first reported a position in ANIP in Q4 2025 and has held it in 3 quarters since. The position peaked at $221K in Q4 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Carnegie Investment Counsel held 2,600 shares of ANI Pharmaceuticals worth $215K as of Q2 2026.
  • Carnegie Investment Counsel sold 200 ANI Pharmaceuticals shares in Q2 2026, an estimated $16K.
  • ANI Pharmaceuticals made up ﹤0.01% of Carnegie Investment Counsel's portfolio in Q2 2026, its #530 holding.
  • Carnegie Investment Counsel first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Carnegie Investment Counsel's ANI Pharmaceuticals position peaked at $221K in Q4 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.